In Venezuela, the harvest of spectacled caiman (Caiman crocodilus) has generated significant economic benefits for citizens and the government wildlife department. Between 1983 and 1995 more than 1 million caiman were harvested, with an export value in excess of $US 115 million. Although limited survey data restrict quantitative comparisons, most indications suggest that the harvest has been within sustainable limits. Hunting is conducted on private lands in the central Venezuelan plains where caiman populations benefit from cattle ranching management activities, particularly the construction of dry‐season water holes. For ranchers, caiman hunting produces a high return on investment, but the overall earnings are small when compared to those produced by cattle. Caiman are mostly a quick and easy source of income that complements cattle ranching, and there is little incentive to actively manage caiman populations. The only evidence that the income from caiman harvests generates economic incentives to protect caiman populations is that landowners sold the skins of caiman illegally hunted in other areas, so as not to reduce their own caiman populations and possibly diminish future hunting quotas. There is no evidence that caiman harvesting generates economic incentives to protect natural habitat, because caiman benefit from human alteration of savanna habitats associated with the much more economically important cattle ranching activities. Recent changes in how hunting quotas are assigned have reduced economic incentives for landowners to protect caiman populations, but the changes have made the quota‐setting procedure simpler. One of the greatest conservation benefits of the program has been its ability to generate operating funds for the traditionally cash‐strapped government wildlife agency through a variety of taxes and user fees. Due to a recent government restructuring, however, program proceeds will now go to the central treasury and will no longer benefit wildlife management programs.
En el grupo A se trataron 363 pacientes de las cuales el 31.96% fueron pre- eclámpticas, 21.49% presentaron preeclampsia grave, inminencia de eclampsia 17.08% tuvieron eclampsia, 7.16% de pacientes presentaron E.V.H.C. con preeclampsia sobreagregada, 12.95% tuvieron E.V.H.C. con inminencia de eclampsia, 3.86% presentaron E.V.H.C. con eclampsia sobreagregada y 4.68% fueron E.V.H.C. puras.La mortalidad materna en las pacientes hipertensas, en el grupo A fue el 5.23% y en el grupo B fue el 0.26%.Se analizaron dos grupos de pacientes sometidas a dos tipos de tratamientos en los estados hipertensivos del embarazo. El primer grupo A tratado sistemáticamente con diuréticos, barbitúricos a largo plazo y conductas especiantes para lograr mayor maduración fetal. El segundo grupo B tratado especialmente con vasodilatadores en el cual las conductas, apoyadas en una evaluación fetal más rigurosa, fue más activa e intervencionista.En relación con el número de partos atendidos en el Instituto, la mortalidad materna en el grupo A es de 13 por 10.000 partos y en el grupo B de 0.9 por 10.000 partos.La mortalidad por toxemia representa el 41% de la mortalidad materna total del Instituto en el grupo A de pacientes analizadas y el 4.3% en el grupo B de pacientes.La mortalidad perinatal, se desglosa minuciosamente; en general la mortalidad perinatal total del grupo A es del 26.17% y en el grupo Bes del 14.32%.La mortalidad perinatal tiene una diferencia altamehte significativa por los análisis estadísticos demostrándose que el segundo grupo de pacientes se han beneficiado por el nuevo sistema de tratamiento.Los beneficios obtenidos no pueden imputarse a un solo parámetro de tratamiento, éstos son el resultado de la suma de todas las nuevas pautas establecidas.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.